Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease

Author

Keywords

*Cardiovascular Diseases/epidemiology/prevention & control

*Diabetes Mellitus, Type 2/complications/drug therapy

*Dipeptidyl-Peptidase IV Inhibitors/therapeutic use

Dipeptidyl-Peptidases and Tripeptidyl-Peptidases

*Heart Failure/epidemiology

Hospitalization

*Myocardial Infarction

Primary health care

*Renal Insufficiency, Chronic/complications/epidemiology

Retrospective Studies

*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use

United Kingdom/epidemiology

Cardiovascular disease

diabetes complications

dipeptidyl peptidase-4 inhibitor

Year of Publication

2021

Journal

Diabetes Obes Metab

Volume

23

Number of Pages

2207-2214

ISBN Number

1462-8902 (Print)1462-8902

Accession Number

33973690

DOI

10.1111/dom.14437